Journal of Clinical Virology Plus (Feb 2023)
Comparison of one single-antigen assay and three multi-antigen SARS-CoV-2 IgG assays in Nigeria
- Nnaemeka C. Iriemenam,
- Fehintola A. Ige,
- Stacie M. Greby,
- Olumide O. Okunoye,
- Mabel Uwandu,
- Maureen Aniedobe,
- Stephnie O. Nwaiwu,
- Nwando Mba,
- Mary Okoli,
- Nwachukwu E. William,
- Akipu Ehoche,
- Augustine Mpamugo,
- Andrew Mitchell,
- Kristen A. Stafford,
- Andrew N. Thomas,
- Temitope Olaleye,
- Oluwaseun O. Akinmulero,
- Ndidi P. Agala,
- Ado G. Abubakar,
- Ajile Owens,
- Sarah E. Gwyn,
- Eric Rogier,
- Venkatachalam Udhayakumar,
- Laura C. Steinhardt,
- Diana L. Martin,
- McPaul I. Okoye,
- Rosemary Audu
Affiliations
- Nnaemeka C. Iriemenam
- Division of Global HIV and TB, Center for Global Health, Centers for Disease Control and Prevention, Abuja, Nigeria; Corresponding author.
- Fehintola A. Ige
- Center for Human Virology and Genomics, Microbiology Department, Nigerian Institute of Medical Research, Yaba, Lagos, Nigeria
- Stacie M. Greby
- Division of Global HIV and TB, Center for Global Health, Centers for Disease Control and Prevention, Abuja, Nigeria
- Olumide O. Okunoye
- Division of Global HIV and TB, Center for Global Health, Centers for Disease Control and Prevention, Abuja, Nigeria
- Mabel Uwandu
- Center for Human Virology and Genomics, Microbiology Department, Nigerian Institute of Medical Research, Yaba, Lagos, Nigeria
- Maureen Aniedobe
- Center for Human Virology and Genomics, Microbiology Department, Nigerian Institute of Medical Research, Yaba, Lagos, Nigeria
- Stephnie O. Nwaiwu
- Center for Human Virology and Genomics, Microbiology Department, Nigerian Institute of Medical Research, Yaba, Lagos, Nigeria
- Nwando Mba
- Nigeria Centre for Disease Control (NCDC), Gaduwa, FCT, Nigeria
- Mary Okoli
- Nigeria Centre for Disease Control (NCDC), Gaduwa, FCT, Nigeria
- Nwachukwu E. William
- Nigeria Centre for Disease Control (NCDC), Gaduwa, FCT, Nigeria
- Akipu Ehoche
- University of Maryland Center for International Health, Education, and Biosecurity (CIHEB), Maryland Global Initiatives Corporation (MGIC), FCT, Nigeria
- Augustine Mpamugo
- University of Maryland Center for International Health, Education, and Biosecurity (CIHEB), Maryland Global Initiatives Corporation (MGIC), FCT, Nigeria
- Andrew Mitchell
- Center for International Health, Education, and Biosecurity, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, USA
- Kristen A. Stafford
- Center for International Health, Education, and Biosecurity, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, USA
- Andrew N. Thomas
- International Research Center of Excellence, Institute of Human Virology, Abuja, Nigeria
- Temitope Olaleye
- International Research Center of Excellence, Institute of Human Virology, Abuja, Nigeria
- Oluwaseun O. Akinmulero
- International Research Center of Excellence, Institute of Human Virology, Abuja, Nigeria
- Ndidi P. Agala
- International Research Center of Excellence, Institute of Human Virology, Abuja, Nigeria
- Ado G. Abubakar
- International Research Center of Excellence, Institute of Human Virology, Abuja, Nigeria
- Ajile Owens
- Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA
- Sarah E. Gwyn
- Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA
- Eric Rogier
- Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA
- Venkatachalam Udhayakumar
- Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA
- Laura C. Steinhardt
- Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA
- Diana L. Martin
- Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA
- McPaul I. Okoye
- Division of Global HIV and TB, Center for Global Health, Centers for Disease Control and Prevention, Abuja, Nigeria
- Rosemary Audu
- Center for Human Virology and Genomics, Microbiology Department, Nigerian Institute of Medical Research, Yaba, Lagos, Nigeria
- Journal volume & issue
-
Vol. 3,
no. 1
p. 100139
Abstract
Objectives: Determining an accurate estimate of SARS-CoV-2 seroprevalence has been challenging in African countries where malaria and other pathogens are endemic. We compared the performance of one single-antigen assay and three multi-antigen SARS-CoV-2 IgG assays in a Nigerian population endemic for malaria. Methods: De-identified plasma specimens from SARS-CoV-2 RT-PCR positive, dried blood spot (DBS) SARS-CoV-2 RT-PCR positive, and pre-pandemic negatives were used to evaluate the performance of the four SARS-CoV-2 assays (Tetracore, SARS2MBA, RightSign, xMAP). Results: Results showed higher sensitivity with the multi-antigen (81% (Tetracore), 96% (SARS2MBA), 85% (xMAP)) versus the single-antigen (RightSign (64%)) SARS-CoV-2 assay. The overall specificities were 98% (Tetracore), 100% (SARS2MBA and RightSign), and 99% (xMAP). When stratified based on <15 days to ≥15 days post-RT-PCR confirmation, the sensitivities increased from 75% to 88.2% for Tetracore; from 93% to 100% for the SARS2MBA; from 58% to 73% for RightSign; and from 83% to 88% for xMAP. With DBS, there was no positive increase after 15-28 days for the three assays (Tetracore, SARS2MBA, and xMAP). Conclusion: Multi-antigen assays performed well in Nigeria, even with samples with known malaria reactivity, and might provide more accurate measures of COVID-19 seroprevalence and vaccine efficacy.
